Tours, France – October 20, 2026 – MAbSilico, a TechBio company leveraging artificial intelligence for therapeutic antibody discovery, today announced its selection
Integrated AI and cell line development workflow aims to reduce manufacturing risks and shorten timelines from sequence design to high-yield production cell